Gerrit Klaerner, Tricida CEO (Nasdaq)
First came the news of strategic review. Now Tricida is letting more than half of its staff go in wake of PhIII flop
As the decisive defeat of its lead and sole drug continues to reverberate, Tricida is laying off 57% of its workforce while it searches for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
